Subtype
Digestive System Neuroendocrine Tumor
CI-CAN-00000823Explore in graph →
Non-malignant62 active trials1 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000823Explore in graph →
Clinical trials
256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | enrolling by invitation | Phase 2 | 46 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 1, 2025 | clinicaltrials |
| Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET |
| enrolling by invitation |
| Phase 1 / Phase 2 |
| 52 |
| National Health Research Institutes, TaiwanOTHER |
| 1 |
| Aug 15, 2025 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2026source: clinicaltrials